Behenic Acid

Behenic Acid

SCHEMBL5360183

CCCCCCCCCCCCCCCCCCCCCC(=O)O.OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IGF2R P11717 1/20 0.51
GJB2 P29033 1/20 0.51
LGALS8 O00214 2/20 0.50
LGALS3 P17931 2/20 0.50
LGALS4 P56470 2/20 0.50
SELL P14151 3/20 0.47
SELP P16109 3/20 0.47
SELE P16581 3/20 0.47
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PTPN1 P18031 1/20 0.45
TLR4 O00206 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cellobiose SCHEMBL5358771 1.00 IGF2R (0.51) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL22034126 1.00 IGF2R (0.51) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL5354201 1.00 IGF2R (0.51) IGF2RGJB2LGALS8LGALS3LGALS4
Maltotriose SCHEMBL17459229 1.00 IGF2R (0.51) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL5360199 1.00 IGF2R (0.51) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL22034051 1.00 IGF2R (0.51) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL7118280 1.00 IGF2R (0.51) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL1546728 0.99 GJB2 (0.50) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL6000113 0.99 GJB2 (0.50) IGF2RGJB2LGALS8LGALS3LGALS4
Cellobiose SCHEMBL6811991 0.94 IGF2R (0.56) IGF2RGJB2LGALS8LGALS3LGALS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103365133-B Production process for colorant, colorant composition, toner, ink for ink jet recording and color filter KONICA MINOLTA BUSINESS TECH 2015-06-17 CN disclosed
US-7205406-B2 Azomethine dye and metal complex dye, as well as color toner and ink-jet ink using the same KONICA MINOLTA HOLDINGS, INC. (JP) 2007-04-17 US disclosed
US-20060073403-A1 Azomethine dye and metal complex dye, as well as color toner and ink-jet ink using the same KONICA MINOLTA HOLDINGS, INC. (JP) 2006-04-06 US disclosed
US-7011701-B2 Dye and ink jet printing ink KONICA MINOLTA HOLDINGS, INC. (JP) 2006-03-14 US disclosed
EP-1231072-B1 Thermal transfer recording material and thermal transfer recording method KONISHIROKU PHOTO IND (JP) 2005-12-14 EP disclosed
US-20040106782-A1 Dye and ink jet printing ink KONICA MINOLTA HOLDINGS, INC. (JP) 2004-06-03 US disclosed
US-6713432-B2 EMPLOYING NOVEL DYES HAVING PYRAZOLOPYRIMIDINE-7-ONE PARENT NUCLEUS KONICA CORPORATION (JP) 2004-03-30 US disclosed
US-20020151437-A1 Thermal transfer recording material and thermal transfer recording method KONICA CORPORATION (JP) 2002-10-17 US disclosed
EP-1231072-A2 Thermal transfer recording material and thermal transfer recording method KONICA CORPORATION (JP) 2002-08-14 EP disclosed
EP-0763569-B1 metal complex methin dye KONISHIROKU PHOTO IND (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106782-A1 Dye and ink jet printing ink IK, SUZ12, H1-10 IGF2R 3812/4885GJB2 3183/4885LGALS8 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.